SCHEMBL4620202

SCHEMBL4620202

CC(NCC1CCCCC1)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.47
CYP2D6 P10635 1/20 0.44
EPHX1 P07099 4/20 0.44
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
MMP1 P03956 1/20 0.42
MMP2 P08253 1/20 0.42
MMP3 P08254 1/20 0.42
MMP9 P14780 1/20 0.42
MMP8 P22894 1/20 0.42
CA9 Q16790 1/20 0.42
EPHX2 P34913 1/20 0.41
OPRK1 P41145 1/20 0.40
ADH1B P00325 1/20 0.39
ADH1C P00326 1/20 0.39
ADH1A P07327 1/20 0.39
ADH4 P08319 1/20 0.39
ADH7 P40394 1/20 0.39
KMT2A Q03164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4619210 1.00 LTA4H (0.47) LTA4HCYP2D6EPHX1CA12CA1
SCHEMBL4620196 1.00 LTA4H (0.47) LTA4HCYP2D6EPHX1CA12CA1
SCHEMBL22413014 0.98 LTA4H (0.44) LTA4HCYP2D6EPHX1CA12CA1
SCHEMBL22413011 0.98 LTA4H (0.44) LTA4HCYP2D6EPHX1CA12CA1
SCHEMBL5592373 0.94 LTA4H (0.41) LTA4HCYP2D6EPHX1CA12CA1
SCHEMBL5592372 0.94 LTA4H (0.41) LTA4HCYP2D6EPHX1CA12CA1
SCHEMBL1377279 0.90 SIGMAR1 (0.42) LTA4HKMT2A
SCHEMBL1377280 0.90 SIGMAR1 (0.42) LTA4HKMT2A
SCHEMBL4620611 0.81 BCHE (0.46) LTA4HEPHX1KMT2AMEN1NPC1
SCHEMBL20422606 0.81 EPHX1 (0.42) LTA4HCYP2D6EPHX1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317803-A1 BCL9 PEPTIDES AND VARIANTS THEREOF WNTRX PHARMACEUTICALS INC. 2024-09-26 US disclosed
US-11591365-B2 BCL9 peptides and variants thereof WNTRX PHARMACEUTICALS INC. (US) 2023-02-28 US disclosed
CN-111836632-A BCL9 peptides and variants thereof 温特瑞克斯制药有限公司 2020-10-27 CN disclosed
EP-3706771-A1 BCL9 PEPTIDES AND VARIANTS THEREOF WNTRX Pharmaceuticals Inc. (US) 2020-09-16 EP disclosed
US-20200262867-A1 BCL9 PEPTIDES AND VARIANTS THEREOF WNTRX PHARMACEUTICALS INC. 2020-08-20 US disclosed
EP-1884230-A1 PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT OR AGENT FOR PREVENTING/AMELIORATING ROUGH SKIN AND EXTERNAL COMPOSITION FOR SKIN Shiseido Company, Limited (JP) 2008-02-06 EP disclosed
US-20070142287-A1 Compositions And Methods For Treatment Of Cancer BIOMED SOLUTIONS, LLC (US) 2007-06-21 US disclosed
US-20060057729-A1 Diffraction grating-based encoded element having a substance disposed thereon ILLUMINA, INC. 2006-03-16 US disclosed
US-5128448-A Peptide hormones HOFFMAN-LA ROCHE INC. (US) 1992-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317803-A1 BCL9 PEPTIDES AND VARIANTS THEREOF BCL9, BCL9L, BCL3 LTA4H 3518/4885CYP2D6 4481/4885EPHX1 4733/4885
US-11591365-B2 BCL9 peptides and variants thereof BCL9, BCL9L, BCL3 LTA4H 3518/4885CYP2D6 4481/4885EPHX1 4733/4885
US-20200262867-A1 BCL9 PEPTIDES AND VARIANTS THEREOF BCL9, BCL9L, BCL3 LTA4H 3518/4885CYP2D6 4481/4885EPHX1 4733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.